LLY-283 is a selective SAM-competitive nucleoside inhibitor of PRMT5 and it demonstrates good brain penetration and significantly prolongs survival in mice with orthotopic glioblastoma models (15). The gene discussed is PRMT5; the disease is glioblastoma.